HCPLive articleshttps://www.hcplive.com/newsHCPLive articles© 2026 MJH Life Sciences™ and HCPLive. All rights reserved.Tue, 13 Oct 2026 22:05:16 +00005en-us14447https://www.hcplive.com/newshttps://www.hcplive.com/logo.webphttps://www.hcplive.com/view/guselkumab-sustains-histologic-healing-in-ulcerative-colitis-over-3-yearshttps://www.hcplive.com/view/guselkumab-sustains-histologic-healing-in-ulcerative-colitis-over-3-years<![CDATA[David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.]]>Tue, 13 Oct 2026 21:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/infant-anaphylaxis-resolves-single-epinephrine-dosehttps://www.hcplive.com/view/infant-anaphylaxis-resolves-single-epinephrine-dose<![CDATA[Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.]]>Tue, 13 Oct 2026 21:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/liberty-prior-anti-drug-antibodies-did-not-blunt-sc-infliximab-after-drug-holidayhttps://www.hcplive.com/view/liberty-prior-anti-drug-antibodies-did-not-blunt-sc-infliximab-after-drug-holiday<![CDATA[In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.]]>Tue, 13 Oct 2026 20:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/oral-icotrokinra-sustains-uc-response-through-76-weeks-in-anthem-uc-ltehttps://www.hcplive.com/view/oral-icotrokinra-sustains-uc-response-through-76-weeks-in-anthem-uc-lte<![CDATA[Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC. ]]>Tue, 13 Oct 2026 20:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/felzartamab-and-the-hidden-injury-of-isolated-mvi-with-yasir-qazi-mdhttps://www.hcplive.com/view/felzartamab-and-the-hidden-injury-of-isolated-mvi-with-yasir-qazi-md<![CDATA[TRANSPIRE investigator Yasir Qazi, MD, explains how isolated MVI can signal kidney transplant injury before creatinine rises.]]>Tue, 13 Oct 2026 20:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/regional-differences-in-saroglitazar-response-in-pbc-with-raj-vuppalanchi-mdhttps://www.hcplive.com/view/regional-differences-in-saroglitazar-response-in-pbc-with-raj-vuppalanchi-md<![CDATA[In an EPICS-III subgroup analysis, Raj Vuppalanchi, MD, explains why saroglitazar’s larger US treatment effect may reflect differences in disease biology.]]>Tue, 13 Oct 2026 19:45:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/adtouch-lebrikizumab-eases-itch-pain-hand-foot-eczemahttps://www.hcplive.com/view/adtouch-lebrikizumab-eases-itch-pain-hand-foot-eczema<![CDATA[Shawn Kwatra, MD, discusses ADtouch data showing lebrikizumab improved clearance, itch, pain, and satisfaction in hand and foot atopic dermatitis.]]>Tue, 13 Oct 2026 19:06:12 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/rezpegaldesleukin-hair-regrowth-climbs-1-year-aa-rosmarinhttps://www.hcplive.com/view/rezpegaldesleukin-hair-regrowth-climbs-1-year-aa-rosmarin<![CDATA[David Rosmarin, MD, discusses 52-week phase 2b REZOLVE-AA data on rezpegaldesleukin in severe alopecia areata presented at EADV 2026.]]>Tue, 13 Oct 2026 18:05:24 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/sibo-tied-to-higher-bile-acid-synthesis-in-patients-with-chronic-diarrheahttps://www.hcplive.com/view/sibo-tied-to-higher-bile-acid-synthesis-in-patients-with-chronic-diarrhea<![CDATA[Ayah Matar, MD, discusses findings showing elevated serum 7αC4 in SIBO-positive patients, suggesting overlap between SIBO and bile acid diarrhea.]]>Tue, 13 Oct 2026 17:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/is-hidradenitis-suppurativa-underdiagnosed-male-patients-https://www.hcplive.com/view/is-hidradenitis-suppurativa-underdiagnosed-male-patients-<![CDATA[US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.]]>Tue, 13 Oct 2026 16:52:34 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/fit-misses-more-crcs-in-women-could-sex-specific-thresholds-help-https://www.hcplive.com/view/fit-misses-more-crcs-in-women-could-sex-specific-thresholds-help-<![CDATA[At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.]]>Tue, 13 Oct 2026 15:15:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/chest-2026-preview-late-breakers-interviewshttps://www.hcplive.com/view/chest-2026-preview-late-breakers-interviews<![CDATA[Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.]]>Tue, 13 Oct 2026 15:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/no-new-safety-signals-over-3-years-hs-bimekizumab-garghttps://www.hcplive.com/view/no-new-safety-signals-over-3-years-hs-bimekizumab-garg<![CDATA[Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.]]>Tue, 13 Oct 2026 14:56:31 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/bile-acid-hdca-reduces-liver-fat-via-ppar-with-takashi-miki-md-phdhttps://www.hcplive.com/view/bile-acid-hdca-reduces-liver-fat-via-ppar-with-takashi-miki-md-phd<![CDATA[A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.]]>Tue, 13 Oct 2026 14:40:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/eadv-2026-recap-top-5-psoriasis-headlineshttps://www.hcplive.com/view/eadv-2026-recap-top-5-psoriasis-headlines<![CDATA[Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.]]>Tue, 13 Oct 2026 14:08:42 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/efruxifermin-shows-durable-antifibrotic-response-in-mash-through-96-weekshttps://www.hcplive.com/view/efruxifermin-shows-durable-antifibrotic-response-in-mash-through-96-weeks<![CDATA[HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.]]>Tue, 13 Oct 2026 14:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/eplontersen-fails-to-achieve-primary-endpoint-improves-kccq-and-6mwt-in-attr-cmhttps://www.hcplive.com/view/eplontersen-fails-to-achieve-primary-endpoint-improves-kccq-and-6mwt-in-attr-cm<![CDATA[These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.]]>Tue, 13 Oct 2026 01:15:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/tovinontrine-50-mg-improves-cgmp-with-minimal-effect-on-nt-probnp-in-hfpefhttps://www.hcplive.com/view/tovinontrine-50-mg-improves-cgmp-with-minimal-effect-on-nt-probnp-in-hfpef<![CDATA[James Udelson, MD, discusses the Cycle-2-PEF trial, which ultimately supports the inverse dose-response hypothesis from companion trial Cycle-1-REF.]]>Mon, 12 Oct 2026 22:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/multilevel-intervention-improves-crc-screening-with-aasma-shaukat-md-mphhttps://www.hcplive.com/view/multilevel-intervention-improves-crc-screening-with-aasma-shaukat-md-mph<![CDATA[A randomized trial at 5 Brooklyn FQHCs found mailed FIT kits and navigation raised 6-month screening completion to 35.9% vs 23.6% with usual care.]]>Mon, 12 Oct 2026 21:59:38 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/tovinontrine-reduces-nt-probnp-in-hfref-may-have-greater-benefit-at-smaller-doseshttps://www.hcplive.com/view/tovinontrine-reduces-nt-probnp-in-hfref-may-have-greater-benefit-at-smaller-doses<![CDATA[James Udelson, MD, discusses the results of the Cycle-1-REF study, presented at HFSA 2026, that could support an inverse dose-response relationship with this PDE9 inhibitor.]]>Mon, 12 Oct 2026 20:48:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/off-the-sidelines-exercise-in-hemophilia-a-with-doris-quon-md-phdhttps://www.hcplive.com/view/off-the-sidelines-exercise-in-hemophilia-a-with-doris-quon-md-phd<![CDATA[How patient priorities shift from childhood to adulthood, and why separating subclinical bleeds from chronic pain remains an unmet need.]]>Mon, 12 Oct 2026 20:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/atopic-dermatitis-biologic-selection-raj-chovatiya-md-phdhttps://www.hcplive.com/view/atopic-dermatitis-biologic-selection-raj-chovatiya-md-phd<![CDATA[Raj Chovatiya, MD, PhD, explains how to approach biologic selection in atopic dermatitis and previews oral, multispecific, and novel-target therapies.]]>Mon, 12 Oct 2026 20:11:34 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/fertility-treatment-in-ibd-insights-from-the-wisdom-cohorthttps://www.hcplive.com/view/fertility-treatment-in-ibd-insights-from-the-wisdom-cohort<![CDATA[Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer. ]]>Mon, 12 Oct 2026 20:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/resmetirom-tied-to-lower-mace-vs-semaglutide-in-real-world-masld-analysishttps://www.hcplive.com/view/resmetirom-tied-to-lower-mace-vs-semaglutide-in-real-world-masld-analysis<![CDATA[A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.]]>Mon, 12 Oct 2026 18:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/dupilumab-improves-esophageal-distensibility-in-eoe-remodel-trialhttps://www.hcplive.com/view/dupilumab-improves-esophageal-distensibility-in-eoe-remodel-trial<![CDATA[Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.]]>Mon, 12 Oct 2026 16:44:36 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/volixibat-reduces-psc-related-pruritus-in-phase-2b-vistas-trialhttps://www.hcplive.com/view/volixibat-reduces-psc-related-pruritus-in-phase-2b-vistas-trial<![CDATA[Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.]]>Mon, 12 Oct 2026 16:30:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/hemophilia-a-care-beyond-zero-bleeds-with-doris-quon-md-phdhttps://www.hcplive.com/view/hemophilia-a-care-beyond-zero-bleeds-with-doris-quon-md-phd<![CDATA[A treatment center director explains how point-of-care ultrasound separates subclinical bleeds from chronic joint pain.]]>Mon, 12 Oct 2026 16:19:29 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/aloft-ipf-admilparant-60-mg-meets-primary-fvc-end-pointhttps://www.hcplive.com/view/aloft-ipf-admilparant-60-mg-meets-primary-fvc-end-point<![CDATA[Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.]]>Mon, 12 Oct 2026 15:15:08 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/rls-1496-actinic-keratosis-gpx4-phase-1b-2ahttps://www.hcplive.com/view/rls-1496-actinic-keratosis-gpx4-phase-1b-2a<![CDATA[Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.]]>Mon, 12 Oct 2026 15:00:00 GMTHCPLiveusHCPLive Articleshttps://www.hcplive.com/view/long-term-risankizumab-data-show-durable-crohn-s-fistula-outcomeshttps://www.hcplive.com/view/long-term-risankizumab-data-show-durable-crohn-s-fistula-outcomes<![CDATA[Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.]]>Mon, 12 Oct 2026 14:30:00 GMTHCPLiveusHCPLive Articles